68 Harley Street London, W1G 7HE · Main Office
Also at Cromwell & Syon Bishops Wood · Multiple Locations
0203 9838 001 Call for Appointments
jessica@oneheartclinic.com Rapid Response to Enquiries
Cardiovascular Risk — Prevention
Cholesterol & Lipid Management
Elevated cholesterol is one of the most powerful — and most treatable — causes of heart attack and stroke. Modern assessment goes far beyond a simple cholesterol test: advanced markers, genetic testing, and a new generation of highly effective therapies are transforming what we can achieve for patients at risk.
The Foundation of Cardiovascular Risk
Why Cholesterol Matters
Cholesterol is not inherently harmful — it is an essential component of every cell membrane and the precursor to many hormones. The problem arises when certain cholesterol-carrying particles accumulate within artery walls, driving the process of atherosclerosis: the progressive build-up of plaque that narrows coronary arteries and, when it ruptures, triggers the blood clots responsible for most heart attacks and strokes.
The key insight from decades of research is that reducing LDL cholesterol saves lives, with a consistent and proportional relationship between lower LDL and lower cardiovascular event rates. This relationship holds across all patient groups — those with established disease and those at risk — and across all effective therapies.
Cholesterol-related risk is largely silent. There are no symptoms of a raised LDL. Patients feel entirely well while plaque accumulates over decades — making regular measurement and proactive treatment the only reliable means of protection.
Standard Blood Test
Understanding Your Lipid Panel
A standard fasting lipid profile measures four values. Each tells a different part of the story — and each has a specific treatment target that depends on your overall cardiovascular risk.
LDL-C
LDL Cholesterol
< 1.8
mmol/L — very high risk target
Low-density lipoprotein — the primary driver of atherosclerosis. LDL particles embed in artery walls and oxidise, triggering inflammation and plaque formation. The treatment target is lower after a heart attack (<1.4 mmol/L) and progressively adjusted to overall risk.
HDL-C
HDL Cholesterol
> 1.0
mmol/L — higher is better
High-density lipoprotein — the so-called "good cholesterol." HDL particles transport cholesterol away from arteries back to the liver for processing. Low HDL is a significant independent risk factor; target is above 1.0 in men and 1.2 in women.
TG
Triglycerides
< 1.7
mmol/L — fasting target
Triglycerides are fat particles that rise with excess carbohydrate, alcohol, obesity, and diabetes. Elevated triglycerides increase cardiovascular risk independently of LDL and impair HDL function. Fasting is required for an accurate measurement.
Non-HDL
Non-HDL Cholesterol
< 2.6
mmol/L — very high risk target
Non-HDL cholesterol is total cholesterol minus HDL — capturing all atherogenic particles including LDL, VLDL, and IDL. It is increasingly preferred over LDL alone as a treatment target, particularly in patients with elevated triglycerides, where it is more accurate.
Treatment targets are not fixed for everyone — they are calibrated to overall cardiovascular risk. After a heart attack or angioplasty, LDL below 1.4 mmol/L (and a >50% reduction from baseline) is recommended. For primary prevention in lower-risk patients, targets are less stringent. Dr Nijjer calculates your individual risk and sets personalised targets at consultation.
Beyond the Standard Test
Advanced Lipid Markers
A standard lipid panel does not capture the full cardiovascular risk picture. In selected patients — those with premature disease, unexplained events despite treated LDL, or a strong family history — these advanced markers provide important additional information that can change management.
Lipoprotein(a)
Lp(a) — an independent, genetically determined cardiovascular risk factor
Lp(a) is a unique lipoprotein particle with an additional protein — apolipoprotein(a) — attached to its surface. It is almost entirely genetically determined, set at birth, and barely influenced by diet, exercise, or standard lipid therapies including statins. Around 20% of the population carry elevated levels, conferring a significantly increased risk of heart attack, stroke, and aortic valve disease.
Lp(a) is measured once in a lifetime — it does not meaningfully change. A level above 50 mg/dL (or 125 nmol/L) is considered raised. Very high levels (>150–180 mg/dL) carry a risk comparable to heterozygous familial hypercholesterolaemia. PCSK9 inhibitors and inclisiran reduce Lp(a) modestly (by 20–30%); dedicated RNA-targeting therapies in late-stage trials may reduce it by over 80%.
Identifying elevated Lp(a) explains residual risk in patients who have achieved excellent LDL control but continue to have events — and triggers cascade testing in first-degree relatives.
Apolipoprotein B
ApoB — the most precise measure of atherogenic particle burden
Every atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a) — carries exactly one apolipoprotein B molecule on its surface. ApoB therefore directly counts the number of atherogenic particles in the blood, which LDL cholesterol alone cannot do accurately.
This distinction matters most in patients with elevated triglycerides, metabolic syndrome, or type 2 diabetes, where LDL cholesterol can appear deceptively normal while ApoB — and atherogenic particle number — is substantially elevated. In these patients, LDL can be misleadingly reassuring.
The target for very high risk patients is ApoB below 65 mg/dL. For most high-risk patients, below 80 mg/dL. Major guidelines increasingly advocate ApoB as the preferred treatment target over LDL cholesterol.
Apolipoprotein A-I
ApoA-I — a functional measure of HDL capacity
HDL cholesterol measures the amount of cholesterol carried by HDL particles, but not their function. Apolipoprotein A-I is the primary structural protein of HDL and reflects the actual number and functional capacity of HDL particles — their ability to perform reverse cholesterol transport, removing cholesterol from artery walls and delivering it to the liver.
Low ApoA-I, even with a seemingly adequate HDL cholesterol level, indicates dysfunctional HDL that offers little protective benefit. This is particularly relevant in patients with central obesity, insulin resistance, and inflammatory conditions, where HDL is present in number but impaired in function.
The ApoB:ApoA-I ratio is emerging as one of the most predictive single measures of cardiovascular risk — capturing both atherogenic burden and protective capacity in a single figure.
Lp-PLA₂
Lipoprotein-associated Phospholipase A₂ — a marker of plaque vulnerability
Lp-PLA₂ is an enzyme produced by inflammatory cells within atherosclerotic plaques. It is carried predominantly on LDL particles and is a direct marker of plaque inflammation and instability — the critical factor that determines whether a plaque is stable and silent or vulnerable to rupture.
Elevated Lp-PLA₂ independently predicts cardiovascular events — heart attack and stroke — beyond what LDL or standard risk scores can capture. It is particularly useful in patients with a borderline risk score where the result would meaningfully change the decision to treat.
Unlike LDL, which reflects particle quantity, Lp-PLA₂ reflects plaque quality — whether the disease already present is quiescent or actively dangerous. This makes it a powerful tool for reclassifying risk in patients who appear lower risk on standard assessment.
Inherited Condition
Familial
Hypercholesterolaemia
Familial hypercholesterolaemia (FH) is an inherited disorder of LDL clearance, affecting approximately 1 in 250 people — making it one of the most common serious genetic conditions in the UK. Despite this prevalence, the vast majority of cases remain undiagnosed.
In FH, mutations in the LDL receptor gene (LDLR), the apolipoprotein B gene (APOB), or the PCSK9 gene impair the liver's ability to remove LDL particles from the circulation. The result is lifelong exposure to very high LDL levels — from birth — dramatically accelerating atherosclerosis. Without treatment, men with FH have a 50% risk of coronary heart disease by age 50; women by age 60.
Characteristic clinical features that raise suspicion include:
- Total cholesterol above 7.5 mmol/L or LDL above 4.9 mmol/L, particularly in a younger patient
- Tendon xanthomata — cholesterol deposits in the Achilles tendon or knuckles; pathognomonic of FH
- Corneal arcus before the age of 45 — a grey-white ring around the iris
- Xanthelasma — yellowish cholesterol deposits around the eyelids
- Premature cardiovascular disease — heart attack in a first-degree relative before age 55 (men) or 65 (women)
Genetic Testing & Cascade Screening
Genetic testing for FH identifies mutations in the three causative genes. A positive result confirms the diagnosis definitively, removes diagnostic ambiguity, and importantly enables cascade testing — systematic genetic screening of first-degree relatives, who each have a 50% chance of carrying the same mutation.
Cascade testing is one of the most cost-effective cardiovascular interventions available. Each confirmed relative can be started on treatment decades before they would otherwise have been diagnosed — and decades before they would have their first preventable event.
The Dutch Lipid Clinic Network (DLCN) score combines LDL level, clinical signs, and family history to estimate the probability of FH before genetic testing. A score above 8 indicates definite FH; genetic confirmation is recommended in all.
FH requires intensive treatment — often combination therapy — to achieve target LDL levels. PCSK9 inhibitors and inclisiran are both available on the NHS for patients with FH who cannot reach targets on standard therapy.
First-Line Management
Diet, Exercise & Lifestyle
Lifestyle modification is the foundation of cholesterol management and remains important even when medications are required. The two reinforce each other: a patient who eats well and exercises regularly will achieve more from any given medication than one who does not.
For primary prevention in lower-risk patients, a meaningful trial of sustained lifestyle change — three to six months — is appropriate before considering medication. For patients with established cardiovascular disease or FH, lifestyle and medication start simultaneously.
Dietary Fat Quality
Replace saturated fats (butter, full-fat dairy, red meat, coconut oil) with unsaturated alternatives — olive oil, avocados, nuts, and oily fish such as salmon, mackerel, and sardines. This substitution reduces LDL by 10–15% in most patients. Trans fats (in some processed foods) are particularly harmful and should be eliminated entirely.
Soluble Fibre
Oats, barley, pulses (lentils and beans), apples, and psyllium husk contain soluble fibre that binds bile acids in the gut, compelling the liver to draw cholesterol from the blood to make more. A daily bowl of oats, for example, can reduce LDL by around 5–7% — a meaningful and entirely safe contribution.
Plant Sterols & Stanols
These naturally occurring plant compounds compete with cholesterol for intestinal absorption. Products fortified with plant sterols — certain margarines and yoghurt drinks — can reduce LDL by 10–15% when consumed at a dose of 2g daily. They are safe, well-tolerated, and additive to statin therapy.
Carbohydrate & Sugar
Excess refined carbohydrate and sugars are the primary drivers of elevated triglycerides. Reducing added sugar, white bread, white rice, and processed cereals significantly lowers triglycerides and, in susceptible patients, raises HDL. A lower-carbohydrate approach benefits the entire lipid profile.
Exercise
150 minutes of moderate aerobic exercise per week — brisk walking, cycling, or swimming — improves the entire lipid profile: modest LDL reduction, meaningful triglyceride lowering, and a clinically significant rise in HDL. Resistance training adds further benefit. Exercise also improves insulin sensitivity, reducing the metabolic drivers of dyslipidaemia.
Weight & Alcohol
Central adiposity is closely linked to elevated triglycerides and low HDL. A 10% reduction in body weight produces meaningful improvements across the lipid panel. Alcohol raises triglycerides substantially in sensitive individuals — even moderate consumption contributes, and abstinence for a period can dramatically normalise triglycerides.
Pharmacological Treatment
Cholesterol-Lowering Medications
Multiple medication classes are available, each working through a different mechanism. They can be combined to achieve greater LDL reduction than any single agent can provide alone. The choice is tailored to the patient's risk, lipid profile, tolerability, and treatment targets.
- Statins Inhibit HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis in the liver. Reduce hepatic cholesterol production, upregulating LDL receptor expression and increasing clearance of LDL from the blood. The cornerstone of lipid therapy with over 30 years of safety data and clear mortality benefit in high-risk populations. 30–55% LDL reduction
- Ezetimibe Inhibits NPC1L1, a transporter in the small intestine responsible for cholesterol absorption. Reduces intestinal cholesterol absorption by approximately 50%, producing an additional LDL reduction when added to a statin. Well tolerated with very few side effects. Available as a fixed-dose combination with statins. 15–20% additional reduction
- Bempedoic Acid An upstream inhibitor of cholesterol synthesis acting on ATP-citrate lyase, a step before HMG-CoA reductase. Importantly, it is only activated in the liver — not in muscle — which means it does not cause the muscle-related side effects associated with statins. A valuable option for patients with genuine statin intolerance. 15–25% LDL reduction
- PCSK9 Inhibitors Evolocumab (Repatha) and alirocumab (Praluent) are monoclonal antibodies that block PCSK9, a protein that degrades LDL receptors. By preserving receptor density on liver cells, they dramatically increase LDL clearance. Administered as a subcutaneous injection every two to four weeks. NHS-funded for qualifying patients with FH or very high risk. 50–60% additional reduction
- Inclisiran A small interfering RNA (siRNA) therapy targeting the PCSK9 messenger RNA in liver cells, preventing the production of PCSK9 at source. Unlike antibodies that neutralise PCSK9 after it is made, inclisiran stops it being synthesised. The result is a sustained, consistent LDL reduction from just two injections per year — an exceptional convenience advantage. ~50% additional reduction
- Fibrates & Omega-3 Fibrates (fenofibrate) are the primary treatment for severely elevated triglycerides. High-dose purified EPA (icosapentaenoic acid — Vascepa/Vazkepa) demonstrated a significant reduction in major cardiovascular events in the REDUCE-IT trial, independent of triglyceride lowering, in patients already on a statin. Available for patients with hypertriglyceridaemia and residual risk. 30–50% TG reduction
The Most Prescribed Lipid Therapy
Statins — What You Need to Know
Statins are among the most extensively studied medications in the history of medicine. The evidence for their benefit in reducing cardiovascular events and death is unequivocal in high-risk patients. Yet they are also among the most frequently discontinued — largely due to concerns that the evidence does not support. Addressing these concerns directly is a central part of Dr Nijjer's approach.
Common Statins in Clinical Use
- Atorvastatin10–80mg once daily — highest potency, most widely used
- Rosuvastatin5–40mg once daily — very high potency, also lowers Lp(a) modestly
- Pravastatin20–40mg once daily — lowest drug interactions, safest in liver/transplant patients
Addressing Common Concerns
Statin Questions Answered
Q
Statins cause muscle pain — I have read this everywhere.
A
Muscle aching is reported by some patients, but placebo-controlled trials show that the rate of genuine statin-related myalgia is substantially lower than patients believe — and considerably lower than reported in observational studies, where the nocebo effect (expecting a side effect and experiencing it as a result) plays a significant role. Serious muscle complications — true myositis with enzyme elevation, or rhabdomyolysis — are rare, affecting fewer than 1 in 10,000 patients at standard doses. If muscle symptoms develop, Dr Nijjer will check a CK level, consider switching statin or reducing dose, or try alternate-day dosing of rosuvastatin — which has a longer half-life and is often tolerated where daily dosing is not.
Q
I have heard statins damage the liver.
A
Minor rises in liver enzymes occur in a small proportion of patients and are almost always transient and clinically insignificant. Serious liver injury from statins is exceptionally rare — far rarer than liver injury from over-the-counter medications such as high-dose paracetamol. Statins are no longer contraindicated in patients with mild or moderate liver disease, and in patients with non-alcoholic fatty liver disease — a condition driven partly by dyslipidaemia — they are often beneficial. Routine liver monitoring is no longer universally recommended for patients on standard statin doses.
Q
Do statins cause diabetes?
A
Statins do cause a modest increase in fasting glucose and a small increase in the risk of developing type 2 diabetes — primarily in patients who are already borderline diabetic. This is real. However, the cardiovascular benefit of statins in patients at elevated cardiovascular risk vastly outweighs this risk. For every patient who develops diabetes on a statin, approximately five cardiovascular events are prevented. The answer is not to avoid statins — it is to monitor glucose and manage any emerging diabetes appropriately.
Q
My cholesterol is caused by my genes — statins won't fix that.
A
This is a common misunderstanding — and for patients with familial hypercholesterolaemia, almost the reverse is true. Statins work by upregulating the LDL receptor — the very protein that is partially dysfunctional in FH. They therefore work well in most FH patients, and the evidence for statin benefit is, if anything, stronger in genetically elevated LDL than in lifestyle-driven elevation. The key point is that high cholesterol — whatever its cause — drives atherosclerosis, and reducing it protects arteries.
Q
I tried a statin and could not tolerate it. Are there alternatives?
A
Yes — and there are several strategies before reaching that conclusion. Switching to a different statin often resolves tolerability issues; trying a lower dose or alternate-day rosuvastatin is frequently successful. If genuine statin intolerance is confirmed, bempedoic acid offers a statin-free LDL reduction without muscle side effects. Ezetimibe, PCSK9 inhibitors, and inclisiran are all available as statin-independent therapies and can achieve substantial LDL reduction in patients who cannot tolerate any statin dose.
Transformative New Treatments
PCSK9 Inhibitors & Inclisiran
Both classes target the PCSK9 pathway — the liver's mechanism for degrading LDL receptors. By preserving more receptors on liver cell surfaces, both dramatically increase LDL clearance. They are now available on the NHS for qualifying patients and represent a genuine step change for those who cannot achieve sufficient LDL reduction on standard oral therapy.
Monoclonal Antibody
PCSK9 Inhibitors
Evolocumab (Repatha) · Alirocumab (Praluent)
PCSK9 inhibitors are monoclonal antibodies — large protein molecules that bind and neutralise the PCSK9 protein in the blood after it has been secreted by the liver. Without PCSK9, LDL receptors are not degraded; more receptors remain on liver cell surfaces and continuously clear LDL from the circulation.
The FOURIER trial (evolocumab) and ODYSSEY OUTCOMES trial (alirocumab) both demonstrated significant reductions in major cardiovascular events — including heart attack and stroke — beyond statin therapy alone.
Administered as a subcutaneous injection every two weeks (or monthly for evolocumab at high dose). The injection is small, well tolerated, and can be self-administered. Side effects are minimal — mild injection site reactions in some patients. Also reduces Lp(a) by 20–30%.
NHS availability: Funded for patients with established cardiovascular disease who cannot achieve LDL target on maximally tolerated statin plus ezetimibe, and for patients with heterozygous or homozygous FH.
~60%
Additional LDL reduction
Every 2–4 wks
Injection frequency
~25%
Lp(a) reduction
RNA Interference Therapy
Inclisiran
Leqvio — the twice-yearly cholesterol injection
Inclisiran takes a fundamentally different approach. Rather than neutralising PCSK9 after it is produced, inclisiran uses RNA interference (siRNA) technology to silence the gene that makes PCSK9 in the first place. It targets and degrades the messenger RNA carrying the instructions for PCSK9 synthesis within liver cells.
The result is that the liver produces far less PCSK9 for an extended period — achieving sustained LDL reduction from just two injections per year (after an initial loading dose at three months). This transforms the adherence challenge: instead of daily tablets or fortnightly injections, a patient needs only two clinic visits annually for their cholesterol therapy.
Tolerability is excellent. The ORION programme of trials demonstrated consistent 50% LDL reductions with a side-effect profile comparable to placebo. Inclisiran is now available on the NHS via GP or specialist prescription for patients with atherosclerotic cardiovascular disease or FH who require additional LDL lowering.
~50%
Sustained LDL reduction
Twice yearly
Injection frequency
siRNA
Mechanism class
Who qualifies? Both therapies are available on the NHS for patients with atherosclerotic cardiovascular disease (prior heart attack, angioplasty, stroke, or peripheral arterial disease) who cannot achieve LDL below 1.8 mmol/L on maximally tolerated statin plus ezetimibe, and for patients with heterozygous FH at elevated risk. Homozygous FH patients qualify for PCSK9 inhibitors regardless of prior therapy. Dr Nijjer can initiate or support referral for both therapies.
Related Topics
Further Reading
Concerned about your cholesterol?
Dr Nijjer offers comprehensive lipid assessment at 68 Harley Street, including advanced markers, familial hypercholesterolaemia screening, and access to the full range of cholesterol-lowering therapies — from lifestyle optimisation to PCSK9 inhibitors and inclisiran.